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Hepatocyte cell death during liver injury was classically viewed
to occur by either programmed (apoptosis), or accidental,
uncontrolled cell death (necrosis). Growing evidence from our
increasing understanding of the biochemical and molecular
mechanisms involved in cell demise has provided an expanding
view of various modes of cell death that can be triggered dur-
ing both acute and chronic liver damage such as necroptosis,
pyroptosis, and autophagic cell death. The complexity of non-
invasively assessing the predominant mode of cell death during
a speciﬁc liver insult in either experimental in vivo models or
in humans is highlighted by the fact that in many instances
there is signiﬁcant crosstalk and overlap between the different
cell death pathways. Nevertheless, the realization that during
cell demise triggered by a speciﬁc mode of cell death certain
intracellular molecules such as proteins, newly generated pro-
tein fragments, or MicroRNAs are released from hepatocytes
into the extracellular space and may appear in circulation have
spurred a signiﬁcant interest in the development of non-inva-
sive markers to monitor liver cell death. This review focuses
on some of the most promising markers, and their potential
role in assessing the presence and severity of liver damage in
humans.
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roparticle; ALT, alanine aminotransferase.Evolving concepts of modes of liver cell death in acute and
chronic liver disease
Growing evidence has demonstrated that several modalities of
hepatocyte cell death occur in both acute and chronic liver dis-
eases [1]. Indeed, excessive cell death has been identiﬁed as a
central mechanism of liver damage in conditions such as acute
and chronic viral hepatitis, alcoholic and non-alcoholic steato-
hepatitis (ASH and NASH), and drug-induced liver injury (DILI)
[2–5]. Sustained hepatocyte cell death has also been implicated
in the development of hepatic ﬁbrosis [6,7]. The understanding
and identiﬁcation of key molecules involved in biochemical cas-
cades leading to cell death in liver pathophysiology have offered
new options for the development and testing of novel pharmaco-
logical and/or gene mediated therapies for patients with various
liver diseases [8–10].
Each cell death pathway can, in principle, be distinguished on
the basis of initiating events, intermediate changes, terminal cel-
lular events, and effect on tissue [11,12]. In addition to the clas-
sical modes of cell death, such as apoptosis and necrosis
(oncosis), several other forms of hepatic cell death have been
described, including autophagic cell death, pyroptosis, and nec-
roptosis [13–15]. Apoptosis, a highly organized and genetically
controlled process, is the most investigated and best deﬁned form
of programmed cell death. Apoptosis is initiated by either mem-
brane receptors (extrinsic pathway) or intracellular stimuli
(intrinsic pathway). However, both pathways result in the activa-
tion of effector caspases 3 and 7, which execute the ﬁnal apopto-
tic changes [16]. Controversy has existed over whether
autophagy functions to initiate or prevent cell death [17].
Autophagy has been characterized as a type of cell death along
with apoptosis and necrosis [18,19]. By contrast, many investiga-
tions have deﬁned protective functions for autophagy [20–22].
Necroptosis is induced by the same death receptors that activate
the extrinsic apoptotic pathway, namely TNF-R1, TNF-R2, and Fas
[23]. Upon interaction of receptor protein kinases 1 and 3 (RIP1
and RIP3), and in the absence of activated caspase 8, cell death
that morphologically resembles necrosis occurs [24]. Pyroptosis,
a novel caspase 1 dependent form of programmed cell death,
was characterized a decade ago by Cookson and Brannan [25].
Inﬂammasome dependent caspase 1 activation initiates (acting
on more than 40 substrates) an inﬂammatory response, as proin-
ﬂammatory cytokines pro-IL-1b and pro-IL-18 are made active
via cleavage. Additionally, caspase 1 introduces the formation
of discretely sized ion-permeable pores in the plasma membrane,
which leads to water inﬂux, cell swelling and ﬁnally cell lysis due14 vol. 60 j 1063–1074
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to increased osmotic pressure [26]. Necrosis, or oncosis, is an
accidental form of cell death with the fatal consequence being
cellular oxygen deprivation whereby the generation of reactive
oxygen species (ROS) leads to mitochondrial dysfunction and a
drop in ATP level below the threshold required to maintain cellu-
lar integrity [1,27]. Morphologically, oncosis is characterized by
cellular swelling (‘oncosis’ in Greek), formation of membrane
blebs lacking cellular organelles, and ﬁnally cell membrane rup-
ture with the release of cellular contents [28,29] (Table 1).
Most forms of cell death have been extensively characterized
in vitro in primary hepatocytes or several immortalized hepato-
cyte cell lines, but only a few have been well deﬁned in vivo using
various experimental animal models or patients with liver dis-
eases. The complexity of studying cellular demise either ex vivo
(explanted liver tissue from animal models or liver biopsy tissue
from humans) or in vivo (model organism and/or humans) comes
from the recognition that, in many instances, hepatic cell death
represents a highly heterogeneous process. Moreover, frequent
overlap and crosstalk between involved pathways may result in
molecular transitions between different modalities. As such, the
lines between programmed and non-programmed cell death
can become blurred in tissues like the liver where dying cells
and phagocytes are typically not in close contact. Therefore cells
experiencing speciﬁc forms of programmed cell death during an
acute or chronic insult could undergo secondary lysis in situ
resulting in a mixed pattern of cell death. Despite these signiﬁ-
cant challenges, the prospect of developing mechanism-based,
non-invasive biomarkers of cell death have gained signiﬁcant
attention. These markers may provide novel clues regarding the
pathophysiology of disease in humans, may help stratify patients
at risk and/or be used alongside current diagnostics to select
patients that are likely to respond to speciﬁc therapies (e.g., cas-
pase inhibitors). In the following sections, we will discuss some
promising and well-studied blood biomarkers of cell death in var-
ious liver diseases. We will touch on their potential for use as
non-invasive tools to monitor liver damage, their role and limita-
tions in identifying cell death mode speciﬁcity and the future
prospect of mechanism-based biomarkers for human liver
disease.Monitoring cell death in vivo – Non-invasive blood biomarkers
Soluble cytokeratin-18 (CK18) and fragmented CK18
The cellular content of the soluble fraction of cytokeratin-18
(CK18), the major intermediate ﬁlament protein in the liver, has
been shown to be released into the extracellular space during cell
death both in vitro and in vivo. Therefore, it has been hypothesized
that blood measurements of soluble CK18 present a viable means
for monitoring epithelial apoptotic cell death. Full length CK18
can be cleaved by caspase-6 and caspases-3 and -7, resulting in
fragments of approximately 30 kDa and 45 kDa respectively
[30]. The 30 kDa fragment can be detected using a speciﬁc anti-
body (M30), while a different antibody (M65) detects both full
length and fragmented forms [31,32] (Fig. 1). It has been postu-
lated that theM30:M65 ratio can effectively differentiate between
apoptotic and necrotic cell death. This concept has recently come
into question for a number of reasons: (1) It is now clear that
apoptosis can occur independently of caspase activation, as many
instances of caspase activation in non-lethal processes have been1064 Journal of Hepatology 2014reported [33]; (2) A number of cell death modes, excluding necro-
sis, are associated with disruption of plasma membrane, which
can result in the release of CK18 (e.g., pyroptosis); (3) In tissues
from complex organisms, cells dying by apoptosis, or other forms
of programmed cell death, can undergo secondary lysis and subse-
quently release CK18. Recently, Kramer and colleagues published
an elegant study assessing the M30:M65 ratio in vitro in a tumor
cell line and in vivo in sera from cancer patients after both were
exposed to pro-apoptotic chemotherapy [34]. Their results show
thatmore than 85% of CK18 released in vitrowas comprised of cas-
pase cleaved CK18, while the M30:M65 ratio in vivowas as low as
0.01. The authors concluded that treatment with a pro-apoptotic,
caspase-activating drug resulted in a massive increase in circulat-
ing full-length CK18 (M65 positive).
Uncovering the importance of increased hepatocyte cell death,
as a result of lipotoxic insults, in the development and progres-
sion of NASH led us to the following hypothesis: measuring circu-
lating levels of soluble CK18 allows us to quantify hepatocyte cell
death and therefore non-invasively diagnose NASH [35]. A recent
meta-analysis showed that plasma CK18 levels exhibit a sensitiv-
ity of 78%, a speciﬁcity of 87%, and an area under the receiver
operating curve (AUROC) of 0.82 (95% CI: 0.78–0.88) in the diag-
nosis of NASH among patients with NAFLD [36]. As shown among
the 231 participants in the PIVENS (Pioglitazone vs. Vitamin E vs.
Placebo for the Treatment of Non-diabetic Patients with Non-
alcoholic Steatohepatitis) trial, every 100-U/L decline in serum
CK-18 was signiﬁcantly associated with overall histological
improvement, the resolution of NASH, an improvement of at least
1 point in steatosis grade, hepatocellular ballooning, and an
improvement in NAFLD activity score (NAS) [37]. The investiga-
tors measured CK18 levels at baseline and at 16, 48, and
96 months thereafter among 231 of the 247 patients enrolled in
the PIVENS trial [37]. Moreover, CK18 was the only NASH bio-
marker included in the recent published AGA/AASLD/ACG guid-
ance for diagnosis and management of NAFLD [38]. The
recommendations were that ‘‘Although serum/plasma CK18 is a
promising biomarker for identifying steatohepatitis, it is prema-
ture to recommend in routine clinical practice.’’ (Strength – 1,
Evidence – B).
Circulating levels of fragmented and full length CK18 have
also been shown to be elevated in various other liver disorders.
Bantel and coworkers have extensively studied hepatocyte cell
death and the release of CK18 in patients with chronic hepatitis
C (CHC) [39,40]. In sera of 59 patients with chronic hepatitis C,
they found a marked increase in CK18 levels. More than 50% of
the CHC patients with normal aminotransferase levels exhibited
elevated serum CK18 levels and 30% of patients with normal ami-
notransferase levels but increased CK18 levels showed advanced
stages of ﬁbrosis [39]. The extent of liver steatosis quantiﬁed in
liver biopsies was closely correlated with serum levels of CK18
in patients with CHC [40]. Measuring CK18 serum levels appeared
to be a more sensitive method to detect early liver injury and
ﬁbrosis when compared to conventional surrogate markers. The
usefulness of serum CK18 levels as a clinical marker for CHC
patients was questioned by a large study in 267 patients with
treatment-naïve CHC [41]. Jazwinski et al. found elevated CK18
levels in CHC patients when compared to controls and while
the stage of ﬁbrosis was associated with increasing serum CK18
levels there was no association between CK18 and the grade of
steatosis [41]. In addition, Yilmaz et al. described higher CK18
levels in patients with NASH than in those with CHC infectionvol. 60 j 1063–1074
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Fig. 1. Signaling pathways for death ligands/receptors and CK18. Full-length CK18 is digested by active caspase-3/6/7 and full-length and fragmented CK18 are released
into the blood vessel. Death ligands bind death receptors followed by the activation of cell death pathways, leading to apoptosis or necrosis. The death complex is composed
of FasL/Fas and FADD (Fas-associated protein with death domain) and triggers apoptosis through (I) activation of caspase-8 and caspase-3 or (II) activation of pro-apoptotic
proteins, such as Bid and Bax, resulting in the assembly of the apoptosome complex (cytochrome c, Apaf-1, and caspase-9) and activation of caspase-3. The death complex is
composed of TNF-a/TNFR1, TRADD (TNF-R associated death domain), TRAF2 (TNF receptor associated factor 2), RIP1 (receptor-interacting protein1), and clAP1, and
activates several pathways: (1) IKKb, (2) c-Jun, (3) TRADD, FADD, and RIP1 complex followed by necrosis, or (4) activation of caspase-8, TRADD, FADD, and RIP1 complex
triggers apoptosis. The death complex composed of TRAIL/TRAIL-R uses similar pathways to Fas/FasL and TNF-a/TNFR1. Death ligands and receptors can be digested by
enzymes such as MMP (Matrix Metalloproteinase) and released into the blood vessel.
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increased hepatocyte loss by apoptosis compared with CHC
patients. While these studies support the association of CHC with
increased circulating levels of CK18 fragments, the potential clin-
ical role and potential utility of these biomarkers in patients with
CHC remains uncertain. In particular, what is the advantage, or
potentially added beneﬁt to the current standard measurement
of viral load determination for clinical decisions? Would these
markers be used to assess the severity of steatosis, or ﬁbrosis?
Further, how would these measurements compare with the var-
ious serologic and imaging modalities in assessing liver ﬁbrosis
in CHC?
Serum CK18 fragments have also been assessed in the context
of chronic hepatitis B. In a study including 115 patients with
HBeAg-negative chronic hepatitis B, serum CK18 fragments cor-
related with serum transaminases, viraemia, and grading score,
but not with ﬁbrosis or steatosis severity [43]. The authors con-
cluded that CK18 fragment levels may be a useful marker for dif-
ferentiation between the inactive HBV carrier state and HBeAg-
negative chronic hepatitis B, but not in estimating the severity
of liver histological lesions among HBeAg-negative chronic hepa-
titis B patients.Journal of Hepatology 2014CK18 aggregates are the main components of Mallory bodies,
a hallmark in the diagnosis of alcoholic liver disease, which made
CK18 seem to be a promising biomarker [44]. Indeed, serum lev-
els of CK18 in heavy drinkers were higher than those of healthy
controls, with serum CK18 levels also being higher in cases of
alcoholic hepatitis when compared to cases of fatty liver [45].
Interestingly, urinary levels of full-length CK18 are increased in
alcoholics [46]. A recent study by Lavallard and colleagues evalu-
ated CK18 and CK18-fragments in serum samples of 143 heavy
alcoholics. They conﬁrmed the ﬁndings of previous studies by
showing a strong correlation of CK18 and CK18 fragment with
Mallory bodies, hepatocyte ballooning, and ﬁbrosis [47]. Elevated
levels of serum hepatocyte death and apoptotic markers were
independent risk factors in predicting severe ﬁbrosis. The authors
concluded that CK18 and CK18-fragment serum levels could be
useful to rapidly evaluate liver injuries and the efﬁcacy of thera-
pies in alcoholic liver disease [47].
The mechanisms of acute liver failure (ALF) in humans are
complex, etiology-dependent, and are thought to be inﬂuenced
by the balance between various cell death modes, mainly necro-
sis and apoptosis, as well as by cellular regeneration [48].
Therefore, measuring biomarkers that can help in the distinctionvol. 60 j 1063–1074 1065
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Fig. 2. The signaling pathway for HMGB1. HMGB1 binds to TLR (Toll-like receptor) 4 and recruits MyD88 followed by NF-jB activation via TRAF6 (TNF receptor associated
factor), IRAK1 (interleukin-1 receptor-associated kinase 1), and IRAK4. HMGB1 also binds to RAGE (receptor for advanced glycan endproducts) and leads to NF-jB activation
via CDC42/Rac1 or Ras/p38 activation. HMGB1 acetylation is mediated by NF-kB, MAPKM, and NFA in the nucleus and is released in the blood vessel correlated with
inﬂammasome activation driven by PKR activation.
Reviewof cell death modes are attractive tools that may help in the
understanding of mechanistic pathways of ALF and serve as
potential prognosis indicators. In an early study in a group of
68 patients with ALF, Bechmann et al. found a strong correlation
of non-spontaneous remission and total CK18 levels as mea-
sured by M65 determination [49]. They implemented a CK18
(M65)-based MELD (model of end-stage liver disease) score by
replacing bilirubin with M65 in the MELD score calculation.
They were able to demonstrate a high sensitivity and speciﬁcity
in predicting survival of ALF patients. However, due to the low
number of patients studied, and the lack of validation cohort,
the accuracy of this new score for the different etiologies of
ALF could not be assessed. The study however provided evi-
dence supporting the concept that measuring different CK18
markers could help in the distinction between the different
types of cell death involved in various forms of ALF. Subse-
quently, the largest study conducted to date by the Acute Liver
Failure Study Group (ALFSG) included a total of 500 patients
with ALF and demonstrated that M30 rather than M65 proved
to be the most effective measurement to predict which patient
would require liver transplantation or die. Based on these
results the authors developed the ALFSG index which includes
coma grade, INR, levels of bilirubin and phosphorus, and log101066 Journal of Hepatology 2014M30 value, and subsequently validated these ﬁndings in a sep-
arate group of 250 patients with ALF [50].
In summary, CK18 and CK18-fragments are elevated in vari-
ous forms of acute and chronic liver injury. CK-18-fragments
have been established as the most reliable blood biomarker for
predicting the presence of NASH in liver biopsy in both adult
and children with NAFLD. Determination of CK-18 fragments as
part of the ALFSG index better predicts outcomes in patients with
ALF than both the King’s College criteria (KCC) and MELD score.
However, CK-18 measurements remain a research tool and are
not currently available in the clinical setting. The role of these
markers in diagnosis, or monitoring, various forms of liver dis-
ease remains unclear and future studies are still needed.
Death receptors and their ligands
Soluble Fas receptors and Fas ligand
Fas (CD95/APO-1) is a death receptor in the tumor necrosis factor
receptor (TNFR) family and is expressed in a variety of tissue [51].
It is activated by the Fas Ligand (FasL/CD95L), which is a member
of the tumor necrosis factor superfamily. Upon binding, the
receptor undergoes trimerization and forms the intracellular
death-inducing signaling complex (DISC) [52]. The DISC includesvol. 60 j 1063–1074
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JOURNAL OF HEPATOLOGYthe Fas-associated protein with death domain (FADD) and trig-
gers either a type I or type II signaling cascade. In type I cells,
cleavage of the initator caspase-8 ultimately results in activation
of apoptotic effector caspases (caspase-3, -6, and -7), whereas in
type II cells the apoptosome complex is released from dysfunc-
tional mitochondria [53] (Fig. 1). The Fas/FasL signaling pathway
has been implicated in various liver pathologies including
Wilson’s disease, alcoholic liver disease (ALD), acute fulminant
hepatitis, as well as chronic viral hepatitis [54–56]. Fas signaling
has also been shown to function as a link between obesity-
associated fatty liver and increased susceptibility to liver damage.
We recently reported in a diet-induced obesity animal model,
and in patients with non-alcoholic steatohepatitis, a signiﬁcant
increase in the abundance of hepatic Fas receptor, which led to
increased liver sensitivity to the endogenous Fas ligand (FasL)
[57]. Moreover, Zou and coworkers showed that chemically
blocking Fas signaling with an inhibitory peptide (YLGA 12-
mer) reverses liver damage in two established models of fatty
liver [58].
Soluble Fas (sFas) is the soluble form of the membrane associ-
ated Fas and is generated by alternative mRNA splicing [59]. The
soluble FasL (sFasL), however is converted frommembrane-bound
FasL by a matrix metalloproteinase (MMP)-like enzyme [60]. Both
sFas and sFasL appear to intriguing non-invasive biomarkers toJournal of Hepatology 2014monitor cell death in the serum. Suzuki and colleagues found that
serum sFasL levels are increased in the acute phase of hepatitis and
their levels vary according to the cause of hepatitis [61]. In another
study, Nakae and colleagues described that sFasL levels were sig-
niﬁcantly higher in patients with ALF when compared to patients
with sepsis. However authors did not observe signiﬁcant differ-
ences in sFas levels [62]. In patients with NASH, we recently dem-
onstrated that serum levels of sFas and sFasL are signiﬁcantly
higher in patients with biopsy-proven NASH when compared to
patientswith simple steatosis [63].We also generated a prediction
model to diagnose NASH that includes CK18 fragments and solu-
ble Fas with a sensitivity and speciﬁcity of 88% and 89%, respec-
tively [63].Soluble TNF receptors and TNF-alpha
Tumor necrosis factor-alpha (TNF-a) is a pleiotropic monocyte-
derived cytokine that has been associated with cancer progres-
sion, severe inﬂammatory diseases, and liver injury [64]. In
order to fulﬁll inﬂammatory reactions in the tissue, TNF-a
binds to two distinct receptors: TNFR1 and TNFR2. While
TNFR1 is expressed in almost all tissue, TNFR2 is expressed
only on inﬂammatory cells. Once TNF-a ligates TNFR1 the
TNF receptor-associated protein with death domain (TRADD)vol. 60 j 1063–1074 1067
Table 1. Different modes of liver cell death.
Apoptosis Necroptosis Autophagic cell death Pyroptosis Necrosis/oncosis
Nucleus Condensation
DNA fragmentation
Normal Condensation (late 
stage)
Condensation
DNA fragmentation
Mild DNA damage
Cytoplasm/
membrane
Blebbing Swelling/disruption Autophagosomes, 
autolysosomes
Swelling/pores Swelling/blebbing
Cellular components Secretion Release Release Release
Main pathway Caspase-3/6/7 RIP1/RIP3 mTOR, Atg Caspase-1 ROS
RIP1/3, receptor interacting protein 1/3; mTOR, mammalian target of rapamycin; Atg, autophagy-related; ROS, reactive oxygen species.
Reviewis recruited to the death domain of TNFR1. TRADD, as the cen-
tral molecule in the TNF signaling cascade, can activate at least
three different, and potentially contradictory, signaling cas-
cades: (1) I-kappa B kinase (IKK) complex which induces pro-
inﬂammatory and anti-apoptotic target genes; (2) c-Jun-kinase
leading to an increase in pro-apoptotic and proliferation related
genes; (3) death-inducing signaling complex (DISC) that
induces apoptosis (Fig. 1).
It is known that inﬂammatory mediators such as cytokines
and adipocyte derived cytokines, termed adipokines, play an
important role in establishing NAFLD and the progression to
more advanced stages of fatty liver diease [65,66]. The role
of TNF-a as a proinﬂammatory mediator in insulin resistance,
a key element in the development of NAFLD, was ﬁrst
described by Hotamisligil almost two decades ago [67]. Treat-
ment with a neutralizing antibody improved insulin resistance
in obese animals, which show TNF-a overexpression in the adi-
pocytes. Notably, hepatic TNF-a and TNFR1 mRNA levels were
increased in patients with NASH when compared to patients
with simple steatosis [68]. A study by Ribeiro et al. supported
these ﬁndings and even found an increase in hepatic TNFR1
mRNA levels in patients with ASH, further underlining this
important principle in liver disease. In their study, hepatocyte
apoptosis was also signiﬁcantly increased in both NASH and
ASH patients [69]. The TNF-a converting enzyme (TACE)
cleaves receptor bound TNF-a and membrane incorporated
TNFR1 or TNFR2, resulting in the release of soluble TNF-a
(sTNF-a) and soluble TNFR1 or TNFR2 (sTNFR1 or sTNFR2) into
the bloodstream [70,71]. Therefore, sTNF-a and sTNFR present
interesting targets for non-invasive biomarkers to monitor cell
death. An early report by McClain et al. described TNF-a
metabolism dysregulation in ASH and reported that cultured
monocytes from AH patients spontaneously produced TNF-a
[72]. Numerous studies by other groups conﬁrmed that
increased serum TNF-a concentrations in patients with ASH
were correlated with disease severity and mortality [73]. Felver
et al. reported elevated plasma TNF-a concentrations in
patients with severe ASH, either on admission or at discharge
30 days later, and found 82% mortality in ASH patients while
100% survival was seen in patients without elevated plasma
TNF-a levels [74]. Bird et al. reported that patients with severe
ASH who subsequently died had higher plasma TNF-a levels
compared to those who survived, they also found that TNF-a
levels signiﬁcantly correlated with serum bilirubin and creati-
nine values [75]. Moreover, serum TNF-a levels were increased
in children, adolescents and adults with NASH [76,77]. Plasma
TNF-a levels also were signiﬁcantly higher in patients with
chronic hepatitis C, with liver cirrhosis, and hepatocellular1068 Journal of Hepatology 2014carcinoma when compared to those with acute or mild chronic
hepatitis C [78]. Additionally, a positive correlation of soluble
TNFR1 and soluble TNFR2 and disease progression were
described in patients with chronic hepatitis C [79].
Soluble TRAIL receptor and TRAIL
The TNF receptor family further incorporates the TNF-related
apoptosis-inducing ligand receptor (TRAIL-R), TRAIL-RI, and
TRAIL-RII, the last two known also as the death receptor 4
(DH4) and DH5 [80]. It has been hypothesized that TNF-related
apoptosis-inducing ligand (TRAIL) can induce apoptosis because
it activates caspases that are, to a wide extent, similar to those
involved in Fas and TNF-a-induced cell death [81] (Fig. 1). TRAIL,
as well as DH4 and DH5, are involved in a variety of diseases
including vascular diseases, cancers, and infectious diseases
[82,83]. All three TNF receptors have been shown to be upregu-
lated in liver samples of patients with HCV-associated chronic
liver injury and liver cirrhosis [84], as well as in patients with
hepatitis B-mediated ALF [85]. Two studies by Malhi and Kahr-
aman and colleagues showed enhanced DR5 expression in the liv-
ers of patients with NASH [86,87]. Furthermore, levels of serum
sTRAIL have been shown to be signiﬁcantly higher in patients
with NAFLD [88], or hepatitis B virus (HBV) infection, when com-
pared to healthy controls [89].
Based on these results, death receptors such as TNFR and
TRAIL-R and their respective ligands are appealing as promising
non-invasive biomarkers to monitor liver damage.High mobility group box 1 (HMGB1)
The high-mobility group box-1 (HMGB1) protein, also known as
high-mobility group 1 (HMG-1) and amphoterin, is a highly con-
served, abundant, non-histone nuclear protein expressed in
almost all eukaryotic cells [90]. Cellular effects of HMGB1 are
induced via signal pathway receptors, such as receptor for
advanced glycan end products (RAGE) and toll-like receptor 4
(TLR4). Both receptors activate NF-jB, whereas RAGE mediates
this activation through Ras/p38 or CDC42/Rac1, TLR4 recruits
MyD88 which then forms a complex involving TRAF6, interleu-
kin-1 receptor-associated kinase 1 (IRAK1), and IRAK4 [91].
Within the nucleus, HMGB1 modulates and ‘ﬂuidizes’ nucleo-
somes, bends DNA, and binds bent chromatin DNA, thus facilitat-
ing transcription of many genes [92] (Fig. 2). As a component of
the innate immune system, the HMGB1 protein functions as a
common signal that alerts the host to cell stress, unscheduled cell
death, and tomicrobial invasion [93]. In response to inﬂammatory
stimuli, HMGB1 can be secreted by numerous cells includingvol. 60 j 1063–1074
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macrophages, natural killer cells, neutrophils and mature den-
dritic cells. Originally, it was thought that HMGB1 was released
from only necrotic, but not apoptotic, cells [94]. Recent studies
indicate that cells dying via apoptosis could also release HMGB1.
In a number of human cancer cell lines HMGB1 is released follow-
ing treatmentwith chemical inducers of cell death (staurosporine,
etoposide, or camptothecin). This release can be diminished via
application of the apoptosis-inhibitor Z-VAD-fmk [95]. Thus the
release of HMGB1 from both apoptotic and necrotic cells can be
observed [96]. The distribution and nuclear transport affecting
the secretion of HMGB1 is controlled by several posttranslational
modiﬁcations such as acetylation, cysteine oxidation, and phos-
phorylation [97,98]. HMGB1 is hyper-acetylated upon activation
with LPS in monocytes and macrophages while unacetylated
HMGB1 is thought to be released by necrotic or damaged cells
[99,100]. Recently, Lamkanﬁ and coworkers described a depen-
dency of HMGB1 secretion on NLRP3 inﬂammasome assembly
and caspase-1 activation. They found that HMGB1 secretion from
LPS-primed macrophages, or Salmonella typhimurium infected
macrophages, required inﬂammasome components, such as apop-
tosis-associated speck-like protein containing a caspase activa-
tion and recruitment domain (ASC), caspase 1 and Nalp3, or
caspase 1 and Ipaf respectively [101]. A subsequent study from
Lu and coworkers showed that inﬂammasome activation in this
context relies on a double-stranded RNA-dependent protein
kinase (PKR, also known as EIF2AK2) [102].
The role of HMGB1 generation during acute liver failure has
been explored in various experimental models. In a partial lobar
liver warm ischemia mouse model Kamo et al. showed that ASC-
mediated caspase-1/IL-1b signaling promotes HMGB1 to pro-
duce a TLR4-dependent inﬂammatory phenotype that leads to
hepatocellular injury [103]. Another study addressed the role
of intracellular HMGB1 in modulating the early activation of
Kupffer cells (KCs) during Concavalin A (Con A) acute liver fail-
ure. The authors found that up-regulation of HMGB1 expression
and the translocation of HMGB1 in KCs corresponded with early
activation of KCs, while blockade of intracellular HMGB1 signif-
icantly inhibited production of pro-inﬂammatory cytokines
[104].
Based on the importance of HMGB1 in the pathogenesis of
liver damage during acute liver injury, as well as the concept
that different forms of this molecule (hyper-acetylated vs. total)
can serve to distinguish various modes of cell death Park and
colleagues examined the role of HMGB1 as biomarker of liver
cell death in acetaminophen (APAP) induced acute liver injury
[105]. They demonstrated in a small pilot study that both total
and hyper-acetylated HMGB1 levels were elevated in the sera
of APAP overdose patients with liver injury compared to over-
dose patients without liver injury and healthy volunteers.
Increased total and acetylated HMGB1 was associated with a
worse prognosis (King’s College Criteria) – patients died or
required liver transplantation – when compared to those with
spontaneous recovery. In a follow-up study by the same group,
total HMGB1 levels in blood were assessed at the time of ﬁrst
presentation to the hospital in a total of 129 patients with
acetaminophen-induced acute liver injury [106]. Total HMGB1
concentrations were found to be superior to serum ALT levels
in identifying acute liver injury within 8 h of the overdose.
Future studies by independent groups to validate these results,
as well as to assess the utility of HMGB1 in non-APAP forms of
acute liver injury, are needed. Unfortunately, to date, there areJournal of Hepatology 2014no speciﬁc antibodies to identify different functional isoforms
of HMGB1, and mass spectrometry-based analysis presently
remains the only option for identiﬁcation. These methods have
several limitations, including issues with reproducibility, oper-
ator dependence requiring skilled, trained analysts and a spe-
cialized proteomic laboratory, as well as low-throughput and
high cost that currently limit their potential role in clinical
medicine.
miRNAs
Small non-coding RNAs 21–25 nucleotides in size are known as
microRNA (miRNA) and play an important role in the regulation
of gene expression [107]. They are generated as a pre-miRNA
and exported from the nucleus. In the cytoplasm, the pre-miR-
NAs are recognized by an endoribonuclease called Dicer, a
member of the RNase III family, and cleaved into 21–25 base
pair long miRNAs. Dicer also unwinds the cleaved portion(s)
to a single strand and loads the miRNA into the RNA-induced
silencing complex (RISC). The miRNA-RISC complex can interact
with the 30-end untranslated region (30UTR) of the target gene’s
messenger-RNA resulting in the suppression of mRNA transla-
tion [107]. The miRNA-RISC complex can also bind directly to
target sequences resulting in the degradation of mRNA [107]
(Fig. 3). Since a single miRNA can have several target genes, it
plays a signiﬁcant role in gene regulation. Indeed, a number of
miRNAs have been implicated in various disease processes,
especially cancer, where miRNAs already serve as biomarkers
[108]. miRNAs also offer an intriguing opportunity as therapeu-
tic targets [109,110]. Several miRNAs are speciﬁcally expressed
or enriched in the liver. The most abundant liver speciﬁc miRNA
is miR-122, which is present in hepatocytes and can be released
into circulation during hepatocyte damage [111,112]. Two inde-
pendent studies by Wang et al. and Su et al. addressing acetami-
nophen (APAP) toxicity in experimental murine models
identiﬁed miR-122 and miR-192 as potential biomarkers. They
showed dose- and time-dependent changes in the blood levels
of these miRNAs that paralleled histopathologic changes of liver
damage [113]. Changes in plasma levels of these miRNAs could
be detected early after APAP exposure and were more sensitive
than ALT measurements in the assessment of liver injury
[113,114]. Based on these results, Park and colleagues studied
the plasma levels of these two miRNAs in a small cohort of
patients with APAP-induced acute liver injury. Both miR-122
and miR-192 were found to be substantially elevated in patients
with APAP-induced acute liver injury when compared to
patients without liver disease [115]. Aforementioned miRNAs
were also elevated when compared to a small group of patients
with non-APAP acute liver injury [115]. In a follow-up study by
the same group, measurement of miR-122, as well as other
markers of cell death, signiﬁcantly outperformed ALT, INR, and
plasma acetaminophen concentration for the prediction of
APAP-induced liver injury [116].
The potential of various miRNAs as biomarkers of disease
severity in various chronic liver conditions have been recently
explored [111]. Yamada and colleagues revealed that serum lev-
els of miR-122, as well as miR-21, miR-34a, and miR-451 were
increased in patients with NAFLD, when diagnosis was based on
ultrasound determination of liver fat, and that miR-122 levels
correlated with the severity of liver steatosis [117]. Further-
more, miR-103/107 levels were increased in liver biopsies fromvol. 60 j 1063–1074 1069
Table 2. Soluble biomarkers in human liver disease.
Biomarker Tested in 
acute liver 
injury
Tested in chronic 
liver disease
Pilot studies 
available
Validation 
studies 
available
Clinical correlation Main cell death mode [Ref.]
CK18 [full length CK18 (M65), fragmented CK18 (M30)] Apoptosis/necrosis
Fragmented CK18 NAFLD/NASH Yes Yes Disease marker [35]
[36]
Full length CK18 NAFLD/NASH Yes No Disease marker [36]
Fragmented CK18 CHC Yes No Disease progression [39]
[40]
Fragmented CK18 CHC Yes No [41]
Fragmented CK18 CHC/NASH Yes No Disease marker
Advanced fibrosis
[42]
Fragmented CK18 Hepatitis B Yes No Disease distinguish [43]
Full length/
fragmented CK18
ALD Yes No Disease marker [45]
[46]
Full length/
fragmented CK18
ALD Yes No Disease progression [47]
Full length CK18 ALF Yes No Disease prediction [49]
Fragmented CK18 ALF Yes Yes Disease prediction [50]
Fas Apoptosis
sTNFR1 CHC Yes No Disease progression [79]
sTNFR2 NASH Yes No Disease marker [77]
sTNFR2 CHC Yes No Disease progression [79]
TRAIL Apoptosis
s-TRAIL NAFLD Yes No Disease marker [88]
s-TRAIL Chronic hepatitis B Yes No Disease severity [89]
HMGB1 Pyroptosis/necrosis
Total/
hyperacetylated 
HMGB1
APAP Yes No Worse prognosis [105] 
[106]
miRNAs Various
miR-122 APAP/
ALF
Yes No Worse prognosis [115]
miR-192 APAP/
ALF
Yes No Worse prognosis [115]
miR-122 NAFLD Yes No Disease severity [117]
miR-122 CHC Yes No [112]
miR-155/125b/146a CHC Yes No Abundance
Liver fibrosis/
inflammation
[120]
miR-29 Cirrhosis Yes No Disease severity [123]
miR-214-
5b/221/222
Yes No Disease severity [125] 
[126]
Microparticles Various
MPs-CD11a(+)/
CD4(+)/CD235(+)
Cirrhosis
Liver fibrosis
Yes No Abundance [135]
MPs-CD14(+) NASH Yes No Disease severity [136]
MPs-CD4(+)/
CD8(+)
CHC Yes No Abundance [136]
Reviewpatients with ALD, NAFLD, and NASH, and those levels were clo-
sely associated with insulin resistance [118,119]. In addition,
Bala and colleagues found that inﬂammation related miRNAs
(miR-155, miR-125b, and miR-146a) were increased in the
plasma of patients with CHC [120]. Another study by the same
group using various experimental mouse models, demonstrated
that circulating levels of these inﬂammation related miRNAs are
different in response to the type of liver injury, such as APAP,
ALD, and TLR9 and TLR4 ligand-induced liver damage [121].1070 Journal of Hepatology 2014The authors also explored mechanism of miRNA release and
found that in ALD and in inﬂammatory liver injury, serum/
plasma miR-122 and miR-155 were predominantly associated
with the vesicles, whereas in DILI/APAP injury these miRNAs
were present mainly in the protein-rich fraction. Consistent
with these results we recently found that in murine models of
NASH, microvesicles containing miR-122 are released by hepa-
tocytes and can be measured in circulation (see below:
‘‘Microparticles’’).vol. 60 j 1063–1074
JOURNAL OF HEPATOLOGY
Several studies showed that liver ﬁbrosis caused by hepatic
stellate cell (HSC) activation could be monitored by miRNAs. Lak-
ner and coworkers recently showed that miR-19b is reduced in
rodent and human liver ﬁbrosis [122]. A similar study found
reduced miR-29 family members in a carbon tetrachloride-
induced mouse model of hepatic ﬁbrogenesis (CCI4), as well as
in patients with advanced liver cirrhosis [123]. Using a bile
duct-ligation ﬁbrosis model in rats, Venugopal et al. described
reduced levels of miR-150 and miR-194 [124]. Similarly, serum
levels of miR-122 inversely correlated with severity of ﬁbrosis
in patients with CHC. The levels were decreased in patients with
severe ﬁbrosis, while patients with early stages of ﬁbrosis and
high inﬂammatory activity showed increased levels of miR-122
[112]. On the other hand, increased levels of miR-214-5p and
miR-221/222 have been observed in rodent and human liver
ﬁbrosis [125,126]. Several key areas for future investigation
include assessing the mechanisms and kinetics of liver microRNA
release into blood and other potential bioﬂuids reservoirs, as well
as establishing the different compartments, such as extracellular
vesicles, that comprise the predominant source of circulating
miRNAs in various liver disease processes. Future prospective
and longitudinal biomarker studies in APAP and non-APAP acute
liver injury, as well as in various chronic liver diseases, will be
required to determine whether miR-122 works in isolation, or
in combination with other miRNAs, in order to create miRNA pro-
ﬁles that can provide added clinical utility and prognostic value
to currently available tools.
Microparticles
Microparticles (MPs) are small membrane vesicles released in a
highly regulated manner from dying or activated cells. MPs
range between 100 and 1000 nm in size and are generated
through cell membrane shedding. This process involves a sort-
ing of membrane proteins into the shed MP and the inversion
of phosphatidylserine from the inner to the outer membrane
during cellular activation, or early apoptosis [127]. MPs can be
classiﬁed as cell-to-cell communicators [128]. They carry spe-
ciﬁc signatures such as surface receptors, integral membrane,
cytosolic and nuclear proteins, and RNAs including miRNAs
from parental cells and deliver these signatures to other cells
[129,130] (Fig. 3). Notably, MPs not only stay in the original tis-
sue, but may also circulate in the bloodstream [131]. The ﬁrst
report of MP release into circulation during liver injury came
from the AM Diehl group where they demonstrated an increase
in blood and bile MPs using a bile duct ligation (BDL) rat model
[132]. The Diehl group went on to show that these MPs contain
biologically active Hedgehog (Hh) ligands and provided evi-
dence suggesting that activation of Hh signals on hepatic sinu-
soid endothelial cells may be an important mechanism by
which MPs contribute to tissue remodeling during chronic
cholestatic liver injury. More recently, our group identiﬁed cir-
culating MPs released in mice with diet-induced NASH as poten-
tial and novel biomarkers for the diagnosis of NASH [133]. We
found that hepatocytes exposed to excess amounts of saturated
fatty acids released membrane-bound microparticles that
induced angiogenesis when administered to mice. Microparti-
cles from the blood of mice with diet-induced steatohepatitis
originated from the liver and triggered migration and tubular
structure formation when applied to an endothelial cell line.
The angiogenic effects of microparticles generated by hepato-Journal of Hepatology 2014cytes exposed to saturated fatty acids, or of those from mice
with diet-induced steatohepatitis, involved the uptake of the
microparticles by endothelial cells, a process that required
Vanin-1, an enzyme located on the surface of the microparticles.
Thus, the pathological angiogenesis that can occur in steatohep-
atitis could be reduced by preventing endothelial cells from
internalizing Vanin-1–positive microparticles from hepatocytes.
The relevance of MP determination in human disease has been
studied in recent pilot studies [134,132]. Rautou et al. reported
elevated circulating levels of leuko-endothelial-derived CD31(+)/
41() MPs, pan-leukocyte-derived CD11a(+) MPs, lymphocyte-
derived CD4(+) MPs, and erythrocyte-derived CD235a(+) MPs
in patients with liver cirrhosis [135]. Two recent studies by Kor-
nek and Schuppan showed that MPs positive for various inﬂam-
matory cell markers such as CD4(+) or CD8(+) T cells, CD14(+)
monocytes, and iNK cells can be detected in the plasma of
patients with various liver conditions [136,137]. Notably, circu-
lating MPs positive for monocyte-marker CD14, or iNK cell mar-
ker, were higher in a small group of patients with NASH when
compared to those with hepatic steatosis, while patients with
chronic hepatitis C infection had increased levels of MPs posi-
tive for CD4 and CD8 T cell markers [136]. Thus, extracellular
vesicles, in particular MPs, are evolving as attractive biomarkers
to diagnose and monitor liver injury in various acute and
chronic liver conditions. MPs not only carry a speciﬁc signature
of the cell of origin, but may also be important in the pathogen-
esis and progression of liver damage.
Future studies to better assess the proﬁle of MPs present in
blood, the mechanisms involved in their generation, and their
potential contribution to the pathogenesis and progression of
liver damage are warranted.Conclusion
Hepatocyte cell death is a central mechanism involved in liver
injury associated with both acute and chronic liver damage. A
growing understanding of the signaling events involved in trig-
gering cell death has allowed for the dissection of the different
molecular pathways that result in hepatocyte cell death. The clas-
sical hepatocyte cell death model has been presented as having
two mutually exclusive forms: programmed, or apoptotic cell
death, vs. accidental, or necrotic cell death, based on morpholog-
ical criteria. However, recent breakthroughs have identiﬁed a
number of cell death modes that present with crosstalk and coop-
eration in the execution of cell death. Recent evidence indicates
that during these processes certain intracellular and surface pro-
teins are cleaved and/or released from hepatocytes, which has
spurred a signiﬁcant interest in the potential for development
of non-invasive markers to monitor liver cell death. The determi-
nation of these markers in experimental models and patients
with various forms of liver disease have provided important clues
about the role of cell death in liver injury and suggested that bio-
markers of cell death may be useful markers of liver damage
(Table 2). In addition, a biomarker panel including detection of
cell death and liver speciﬁcity will possibly increase accuracy of
diagnosis. Future studies to better assess these markers in differ-
ent types of acute and chronic liver injury, as well as to identify
novel markers of hepatocyte cell death, are warranted and may
provide crucial help in the diagnosis, monitoring and treatment
of liver disease.vol. 60 j 1063–1074 1071
ReviewKey Points
• Non-invasive biomarkers of cell death are evolving as 
promising tools to diagnose and monitor liver damage 
in various acute and chronic liver diseases
• Various markers in blood have been proposed to allow 
the distinction between different modes of cell death 
in the liver contributing to the pathogenesis of liver 
damage. However, several limitations of current assays 
remain to be addressed
• Determination of soluble CK18 fragments is currently 
the most reliable single blood marker for diagnosis of 
NASH
• Determination of CK-18 fragments as part of the 
ALFSG index better predicts outcomes in patients with 
ALF than both the King’s College criteria (KCC) and 
MELD score
• Death receptors such as TNFR and TRAIL-R and their 
respective ligands are appealing as promising non-
invasive biomarkers to monitor liver damage
• Measurement of various functional isoforms of HMGB1 
in blood may be used to assess the predominant types 
of cell death occurring during liver injury
• In pilot studies both acetylated and total HMGB1 are 
better predictors of outcomes in patients with APAP-
ALI than serum liver enzymes, but independent, larger 
validation studies are needed
• Both microRNAs, and extracellular vesicles have 
various features that make them potentially ideal 
mechanism-based biomarkers with strong supporting 
experimental data. Currently, there are only a few very 
small pilot studies in humans and future studies are 
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